NCT02368691View on ClinicalTrials.gov

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 22, 2017

Study Completion Date

September 22, 2017

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

GTx-024

GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg

Trial Locations (7)

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

33308

Holy Cross Hospital, Fort Lauderdale

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

33805

Lakeland Regional Health Care/Cancer Center, Lakeland

38120

The West Clinic, PC, Memphis

59102

St. Vincent Frontier Cancer Center, Billings

77024

US Oncology / Texas Oncology, P.A., Houston

Sponsors

Lead Sponsor

GTx
All Listed Sponsors
lead

GTx

INDUSTRY

NCT02368691 - Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) | Biotech Hunter | Biotech Hunter